Clinical Trial

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Study acronym: EASE SBS 6
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to understand the safety and efficacy of twice weekly glepaglutide 10 mg in adult patients with short bowel syndrome (SBS), who were previously enrolled in the EASE SBS 2 or EASE SBS 3 trials. Participants currently on these trials will be able to continue their glepaglutide treatment by enrolling in this EASE SBS 6 extension trial. The trial includes a 24-month treatment period, followed by a 4-week safety follow-up period. Participants will attend trial visits, where they may undergo heart tests (electrocardiogram (ECG)), vital sign checks, colonoscopies, blood and urine tests, and physical exams.
Protocol Amendment History 2 changes
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-07-31
notable Enrollment reduced: 35 -> 28 participants 2026-07-31
Trial Details
NCT Number NCT07228403
Lead Sponsor Zealand Pharma
Conditions Short Bowel Syndrome (SBS)
Enrollment 28 participants
Start Date 2025-12-11
Primary Completion 2028-09-18 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30